Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Arecor Therapeutics PLC (AIM:AREC)'s chief executive Sarah Howell said the company is at an advanced stage of recruiting patients for phase one trials of rapid ultra-concentrated insulin and should be ready to announce the results at the end of the first quarter of 2024.    The new and ultra-concentrated formulation developed by Arecor has been designed to accelerate the absorption of insulin, a hormone made by the pancreas, after injection.

Arecor's novel drug formulations could help cut burden on hospitals

In studies, Eli Lilly's Mounjaro has demonstrated that it is more effective in helping people lose weight than Ozempic. Street analysts project the weight-loss market to be massive.

Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.

Arcturus Therapeutics

Vertex Pharmaceuticals

With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024

Merchants Bancorp

Perdoceo Education

Perdoceo Education (PRDO), Novo Nordisk (NVO) and Merchants Bancorp (MBIN) have been selected as the top picks with a high net income ratio.

3 Best Profitable Stocks to Invest in Using Net Income Ratio

Eli Lilly

Weight loss drugs are expected to be some of the best-selling pharma products of all time by 2030. Eli Lilly and Novo Nordisk are the frontrunners in this space.

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?

Novo Nordisk reported strong Q3 results, beating analyst consensus on both top line and earnings. The SELECT CVOT study showed that Wegovy/Ozempic treatment may reduce the risk of death from cardiovascular disease by 18%. Novo Nordisk's investments in supply capacity expansion position the company for supercharged growth through 2030.

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Amgen

AstraZeneca

Bristol-Myers

Gilead Sciences

Merck

Novartis

Pfizer

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.

Novo, Lilly rivals explore booming weight-loss drug market entry

Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.

Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

Axonics ModulationTechnologies Inc

Cava Group, Inc.

Goldman Sachs Small Cap Core Equity ETF

iRhythm Technologies

Meritage Homes

Sweetgreen

Shake Shack

Tenable Holdings Inc

Wingstop

Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.

Goldman Sachs money manager digs into three themes for long-term growth

JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top tips were Novo Nordisk, AstraZeneca PLC (LSE:AZN), and Merck KGaA in the large-cap space, Argenx and DiaMonTech in mid-caps, and MorphoSys AG in small caps.

AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why

Having developed a blockbuster diabetes treatment that has gained huge traction in the weight loss market, Novo Nordisk (NYSE:NVO) is now expanding its focus to include the prevention of obesity, according to the Financial Times. CEO Lars Fruergaard Jørgensen is spearheading efforts to explore why certain individuals are more prone to weight gain, the paper said.

Novo Nordisk: From diabetes to weight loss to obesity preventions

Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will get a rain check, and its 2019 call that Germany will enter a recession.

No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers try the medication that was originally approved for type 2 diabetes patients.

Ozempic vs. Mounjaro:: Battle of the bulge

Roche Holding AG

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug market.

Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen Novo Nordisk become Europe's most valuable company.

Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic

Novo Nordisk is a big name in diabetes and obesity care. Both Wegovy and Ozempic are fast-growing drugs with a ton of upside.

Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?

Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.

Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes

Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found.

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.

Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.

The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.

Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs

The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.

Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs

Novo Nordisk on Thursday said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%.

Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies

Li Auto Inc.

MongoDB

With the November rally in the SPDR S&P 500 ETF Trust NYSEARCA: SPY, a number of large-cap stocks are in buy range. Among those names are three large companies that are not S&P 500 components: Li Auto Inc. NASDAQ: LI, MongoDB NASDAQ: MDB and Novo Nordisk A/S NYSE: NVO.

Watch the buy range for Li Auto, MongoDB, Novo Nordisk

New real-world data show that Lilly's Mounjaro helped patients achieve significantly greater weight loss than Ozempic did. This demonstration of Mounjaro's efficacy could lead to a shift in prescribing patterns that hurt Novo Nordisk.

Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?

News for Novo Nordisk Stock (NVO)